Trial results

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

NCT01777282 on ClinicalTrials.gov · last registry update 2017-05-03

Finished 27 January 2015, after enrolling 374 people. Primary outcome, as filed: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE). albiglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P3

Drug

albiglutide

Tanzeum

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Enrollment

374

Started

2013-02-23

Primary completion

2015-01-27 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE)

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the albiglutide page for this molecule’s full trial and approval history.